PeptideStack
5.2kquestions
20kanswers
220users

Is a 97.6% result from VendorInvestigate comparable to 99.1% from Medutest?

Asked 6 Sept 2024Modified 19 months agoViewed 16k times
31

Concretely: 97.6% · VendorInvestigate · 99.1% · Medutest.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Under what conditions does the answer flip?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
RP
askedretest_please13k286 Sept 2024

5 Answers

Sorted by votes
70

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

Concretely, detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
MO
answeredmarta_okonkwo87k25819 Sept 2024
3Do you have a reference for the last claim? Not disputing it, just want to read it. – micron22 5 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
52

Mechanically, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The part that matters: the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 24 Dec 2024 by nkem_obiora — expanded the table to cover the lower concentration

shareimprove this answerflag
NO
answerednkem_obiora46k3815 Dec 2024
41

Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
GS
answeredgradient_slope41k3826 Dec 2024
34

Worth being precise here: the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
CL
answeredcold_lane14k186 Oct 2024
2

The relevant detail is that area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
KL
answeredkirsi_lahtinen45k388 Sept 2024
5I have seen exactly this failure mode twice and both times it was the diluent. – Dr_Yusuf_Adeyemi 9 months ago
4The distinction between purity and content cannot be repeated often enough here. – Dr_Aoife_Brennan 7 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.